Clinical Trial Update: A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of ACE-031 in healthy postmenopausal women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscular Atrophy

Drugs mentioned

• ACE-031

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Muscular Atrophy | Phase 1 | Status: COMPLETED